This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.
MS Beeri , P Werner , M Davidson , S Noy (2002). The cost of behavioral and psychological symptoms of dementia (BPSD) in community dwelling Alzheimer's disease patients. International Journal of Geriatric Psychiatry 17, 403–408.
M Cantillon , R Brunswick , D Molina , M Bahro (1996). Buspirone vs. haloperidol: a double-blind trial for agitation in a nursing home population with Alzheimer's disease. American Journal of Geriatric Psychiatry 4, 263–267.
JL Cummings , M Mega , K Gray , S Rosenberg-Thompson , DA Carusi , J Gornbein (1994). The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 44, 2308–2314.
N Egashira , K Iwasaki , A Ishibashi , K Hayakawa , R Okuno , M Abe , N Uchida , K Mishima , K Takasaki , R Nishimura , R Oishi , M Fujiwara (2008). Repeated administration of Yokukansan inhibits DOI-induced head-twitch response and decreases expression of 5-hydroxytryptamine (5-HT)2A receptors in the prefrontal cortex. Progress in Neuro-Psychopharmacology & Biological Psychiatry 32, 1516–1520.
MF Folstein , SE Folstein , PR McHugh (1975). Mini-Mental State: a practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatry Research 12, 189–198.
N Herrmann , KL Lanctôt (2006). Atypical antipsychotics for neuropsychiatric symptoms of dementia: malignant or maligned? Drug Safety 29, 833–843.
K Iwasaki , S Kabayashi , Y Chimura , M Taguchi , K Inoue , S Cho , T Akiba , H Arai , JC Cyong , H Sasaki (2004). A randomized, double-blind, placebo-controlled clinical trial of the Chinese herbal medicine ‘BaWei Di Huang Wan’ in the treatment of dementia. Journal of American Geriatric Society 52, 1518–1521.
K Iwasaki , M Maruyama , N Tomita , K Furukawa , M Nemoto , H Fujiwara , T Seki , M Fujii , M Kodama , H Arai (2005a). Effects of the traditional Chinese medicine Yi-Gan San for cholinesterase inhibitor-resistant visual hallucinations and neuropsychiatric symptoms in patients with dementia with Lewy bodies. Journal of Clinical Psychiatry 66, 1612–1613.
K Iwasaki , T Satoh-Nakagawa , M Maruyama , Y Monma , M Nemoto , N Tomita , H Tanji , H Fujiwara , T Seki , M Fujii , H Arai , H Sasaki (2005b). A randomized, observer-blinded, controlled trial of the traditional Chinese medicine Yi-Gan San for improvement of behavioral and psychological symptoms and activities of daily living in patients with dementia. Journal of Clinical Psychiatry 66, 248–252.
H Kanatani , H Kohda , K Yamasaki , I Hotta , Y Nakata , T Segawa , E Yamanaka , N Aimi , S Sakai (1985). The active principles of the branchlet and hook of Uncaria sinensis Oliv. examined with a 5-hydroxytryptaomine receptor binding assay. Journal of Pharmacy and Pharmacology 37, 401–404.
MK Lai , SW Tsang , PT Francis , MM Esiri , J Keene , T Hope , CP Chen (2003). Reduced serotonin 5-HT1A receptor binding in the temporal cortex correlates with aggressive behavior in Alzheimer's disease. Brain Research 974, 82–87.
MP Lawton , EM Brody (1969). Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 9, 179–186.
IG McKeith , D Galasko , K Kosaka , EK Perry , DW Dickson , LA Hansen , DP Salmon , J Lowe , SS Mirra , EJ Byrne , (1996). Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 47, 1113–1124.
G McKhann , D Drachman , M Folstein , R Katzman , D Price , EM Stadlan (1984). Clinical diagnosis of Alzheimer's disease: report of health and human services task force on Alzheimer's Disease. Neurology 34, 939–944.
Y Murakami , Q Zhao , K Harada , M Tohda , H Watanabe , K Matsumoto (2005). Choto-san, a Kampo formula, improves chronic cerebral hypoperfusion-induced spatial learning deficit via stimulation of muscarinic M1 receptor. Pharmacology Biochemistry and Behavior 81, 616–625.
S Sato , K Mizukami , T Asada (2007). A preliminary open-label study of 5-HT1A partial agonist tandospirone for behavioural and psychological symptoms associated with dementia. International Journal of Neuropsychopharmacology 10, 281–283.
LS Schneider , K Dagerman , PS Insel (2006). Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. American Journal of Geriatric Psychiatry 14, 191–210.
LS Schneider , KS Dagerman , P Insel (2005). Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. Journal of the American Medical Association 294, 1934–1943.
A Takeda , H Itoh , H Tamano , M Yuzurihara , N Oku (2008). Suppressive effect of Yokukansan on excessive release of glutamate and aspartate in the hippocampus of zinc-defficient rats. Nutritional Neuroscience 11, 41–46.
K Terasawa , Y Shimada , T Kita (1997). Choto-san in the treatment of vascular dementia: a double-blind, placebo-controlled study. Phytomedicine 4, 15–22.
PS Wang , S Schneeweiss , J Avorn , MA Fischer , H Mogun , DH Solomon , MA Brookhart (2005). Risk of death in elderly users of conventional vs. atypical antipsychotic medications. New England Journal of Medicine 353, 2335–2341.
S Yamaguchi , M Matsubara , S Kobayashi (2004). Event-related brain potential changes after Choto-san administration in stroke patients with mild cognitive impairments. Psychopharmacology 171, 241–249.